Arrowhead Pharmaceuticals Inc (LTS:0HI3)
$ 20.17 0.04 (0.2%) Market Cap: 2.56 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 51/100

Arrowhead Pharmaceuticals Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 06:00PM GMT
Release Date Price: $60.32
Patrick Trucchio
H.C. Wainwright & Co. - Senior Biotech Analyst

Welcome back, everyone, to the 5th Annual H.C. Wainwright NASH Conference. My name is Patrick Trucchio, and I am a senior biotech analyst at H.C. Wainwright. It is my pleasure to introduce our next presenter, James Hamilton, Senior VP of Discovery and Translational Medicine at Arrowhead Pharmaceuticals, a clinical stage biopharmaceutical company developing medicines to treat intractable disease by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

Questions & Answers

Patrick Trucchio;James Hamilton<
H.C. Wainwright & Co. - Senior Biotech Analyst

So just to begin, James, if we could start with an overview of the Arrowhead TRiM platform, where it is today and where it could go in the future and why it could conceivably be an ideal platform to develop a potential therapy for NASH?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot